TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03615768

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adapalene-Clindamycin Combination Gel
Description: 5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene Gel
Description: Differin 0.1% Gel, applied nightly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Gel
Description: Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
Study: NCT03682484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-0211
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-0211
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-0211
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01717274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot saline irrigation
Description: The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
Study: NCT01541215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
Study: NCT02906813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Tablets
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Tablets
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Tablets
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Oral Solution
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Oral Solution
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935 Oral Solution
Description: Oral solution
Study: NCT02214563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Study: NCT01226693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 material sparing tablet
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 with sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 with sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 material sparing tablet
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 material sparing tablet
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 without sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 without sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 material sparing tablet
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 without sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 with sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 with sodium lauryl sulphate
Description: oral, 6mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 Phase2b/3 without sodium lauryl sulphate
Description: oral, 6mg, single dose
Study: NCT00973310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Therapy and EGFR-TKI target therapy
Description: Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
Study: NCT03710707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL201
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL201
Description: Oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral repeating dose
Study: NCT01773239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARA computer-based exercises
Study: NCT02285933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
Study: NCT04509050

Intervention type: DRUG
Intervention: Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Description: In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
Study: NCT00242892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra coronary measures of pressure
Description: Intra coronary measures of pressure
Study: NCT02542215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: Cobiprostone 30 mcg oral spray
Study: NCT03391050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral administration
Study: NCT04594720

Intervention type: OTHER
Intervention: Identification group
Description: papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)

Intervention type: OTHER
Intervention: Validation group
Description: papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
Study: NCT00804999

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clear Care
Description: neutralized Clear Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReNu
Description: overnight soak in solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE
Description: overnight soak in solution
Study: NCT01182519

Intervention type: BEHAVIORAL
Intervention: questionnaire, blood draw and urine sample
Description: Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.

Intervention type: BEHAVIORAL
Intervention: questionnaire, blood draw and urine sample
Description: Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
Study: NCT02861833

Intervention type: OTHER
Intervention: nursing support
Description: Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
Study: NCT02090933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation
Study: NCT01655251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study: NCT03133728

Intervention type: DIAGNOSTIC_TEST
Intervention: Alere Q Testing
Description: Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
Study: NCT03887598

Intervention type: DEVICE
Intervention: Ultrasound diagnosis
Description: Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
Study: NCT00806962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant/Excipients
Description: intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: intranasal, puff of air, 2 doses, 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk VLP Vaccine
Description: intranasal, 50mcg, 2 doses--21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk VLP Vaccine
Description: Intranasal, 100 mcg, 2 doses, 21 days apart
Study: NCT00633698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid (niacin)
Description: oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
Study: NCT04313296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)
Description: The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
Study: NCT04096651

Intervention type: OTHER
Group type: OTHER
Intervention: gait recordings
Description: gait recordings

Intervention type: OTHER
Group type: OTHER
Intervention: gait recordings
Description: gait recordings

Intervention type: OTHER
Group type: OTHER
Intervention: gait recordings
Description: gait recordings

Intervention type: OTHER
Group type: OTHER
Intervention: brain magnetic resonance imaging
Description: brain magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: brain magnetic resonance imaging
Description: brain magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: brain magnetic resonance imaging
Description: brain magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: oculomotor movement recordings
Description: oculomotor movement recordings

Intervention type: OTHER
Group type: OTHER
Intervention: oculomotor movement recordings
Description: oculomotor movement recordings

Intervention type: OTHER
Group type: OTHER
Intervention: oculomotor movement recordings
Description: oculomotor movement recordings
Study: NCT04761445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straumann Standard Plus implant and JDental care (JD) Octa implant
Description: Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straumann Standard Plus implant and JDental care (JD) Octa implant
Description: Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
Study: NCT03316222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561
Description: Escalating doses to be administered 3 times a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561
Description: Escalating doses to be administered 3 times a week.
Study: NCT02394288

Intervention type: PROCEDURE
Intervention: Extremity orthopedic or trauma surgery
Description: hip, leg, shoulder, arm
Study: NCT02879773

Intervention type: RADIATION
Intervention: CTPVe
Description: Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
Study: NCT02542215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care - Chemotherapy
Description: Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care - Chemotherapy
Description: Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Care - Radiation
Description: Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care - Radiation
Description: Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
Study: NCT01903863

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
Study: NCT03231735

Intervention type: DEVICE
Group type: OTHER
Intervention: Mid frequency ventilation
Description: Mechanical ventilator used at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard frequency ventilation
Description: Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
Study: NCT04600089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
Study: NCT02943031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Precision Therapy Programs
Description: After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
Study: NCT02329821

Intervention type: OTHER
Intervention: hartmann solution
Description: hartmann solution infusion in patients for hepatic resection

Intervention type: OTHER
Intervention: hartmann solution
Description: hartmann solution infusion in patients for hepatic resection
Study: NCT01461083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MPPF
Description: Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
Study: NCT04390061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Jak-1/3 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Standard Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Standard Therapy
Study: NCT01336296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid
Description: Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid
Description: Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
Study: NCT02209831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS
Description: single dose

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 796 BS
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 5 days
Study: NCT01140373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: engineered autologous T cells
Description: Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
Study: NCT03987776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory energy-restricted diet
Description: During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control energy-restricted diet
Description: During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)